Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-CD73 ANTIBODIES AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/137598
Kind Code:
A1
Abstract:
Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

Inventors:
WANG ZHENGYI (CN)
FANG LEI (CN)
GUO BINGSHI (CN)
ZANG JINGWU (CN)
Application Number:
PCT/CN2018/073746
Publication Date:
August 02, 2018
Filing Date:
January 23, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
I MAB (KY)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C07K16/40; G01N33/53
Domestic Patent References:
WO2016081748A22016-05-26
WO2016081746A22016-05-26
WO2016055609A12016-04-14
WO2016075176A12016-05-19
WO1998052976A11998-11-26
WO2000034317A22000-06-15
WO1991009967A11991-07-11
WO1998046645A21998-10-22
WO1998050433A21998-11-12
WO1998024893A21998-06-11
WO1998016654A11998-04-23
WO1996034096A11996-10-31
WO1996033735A11996-10-31
WO1991010741A11991-07-25
WO1998024893A21998-06-11
WO2011008709A12011-01-20
WO2013112741A12013-08-01
WO2014047624A12014-03-27
WO2013027802A12013-02-28
WO2013034933A12013-03-14
WO2009017833A22009-02-05
WO2009035791A12009-03-19
WO2011097513A12011-08-11
WO2012027721A22012-03-01
WO2005113556A12005-12-01
WO2013052699A22013-04-11
WO2013116562A12013-08-08
WO2014100765A12014-06-26
WO2014100767A12014-06-26
WO2014201409A12014-12-18
Foreign References:
US5892019A1999-04-06
US6150584A2000-11-21
US6458592B12002-10-01
US6420140B12002-07-16
US5585089A1996-12-17
US5693761A1997-12-02
US5693762A1997-12-02
US6190370B12001-02-20
US4694778A1987-09-22
US4946778A1990-08-07
US5258498A1993-11-02
US5807715A1998-09-15
US4816567A1989-03-28
US4816397A1989-03-28
EP0239400A21987-09-30
US5225539A1993-07-06
US5530101A1996-06-25
EP0592106A11994-04-13
EP0519596A11992-12-23
US5565332A1996-10-15
US4444887A1984-04-24
US4716111A1987-12-29
US5413923A1995-05-09
US5625126A1997-04-29
US5633425A1997-05-27
US5569825A1996-10-29
US5661016A1997-08-26
US5545806A1996-08-13
US5814318A1998-09-29
US5939598A1999-08-17
US5658570A1997-08-19
US5693780A1997-12-02
US5756096A1998-05-26
US4980286A1990-12-25
US4965288A1990-10-23
US4997854A1991-03-05
US4943593A1990-07-24
US5021456A1991-06-04
US5059714A1991-10-22
US5120764A1992-06-09
US5182297A1993-01-26
US5252608A1993-10-12
US20040248871A12004-12-09
US20090142345A12009-06-04
US20110287011A12011-11-24
US8450321B22013-05-28
US20160194407A12016-07-07
Other References:
ANTONIOLI, L. ET AL.: "Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities", TRENDS IN CANCER, vol. 2, no. 2, 29 February 2016 (2016-02-29), pages 95 - 109, XP055529454
ALLARD, B. ET AL.: "Targeting CD 73 and downstream adenosine receptor signaling in triple- negative breast cancer", EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 18, no. 8, 6 May 2014 (2014-05-06), pages 863 - 881, XP055267045
STAGG, J. ET AL.: "Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis", PNAS, vol. 107, no. 4, 26 January 2010 (2010-01-26), pages 1547 - 1552, XP055245510
GEOGHEGAN ET AL., MABS, vol. 8, no. 3, 8 February 2016 (2016-02-08), pages 454 - 467
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 2007
HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 448
RANGERPEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
ROUX ET AL., J. IMMUNOL, vol. 161, 1998, pages 4083
ARNON ET AL.: "Monoclonal Antibodies And Cancer Therapy", 1985, ALAN R. LISS, INC., article "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", pages: 243 - 56
HELLSTROM ET AL.: "Controlled Drug Delivery", 1987, MARCEL DEKKER, INC., article "Antibodies For Drug Delivery", pages: 623 - 53
THORPE ET AL.: "Monoclonal Antibodies '84: Biological And Clinical Applications", 1985, article "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", pages: 475 - 506
"Monoclonal Antibodies For Cancer Detection And Therapy", 1985, ACADEMIC PRESS, article "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", pages: 303 - 16
THORPE ET AL.: "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., vol. 52, 1982, pages 119 - 58, XP001179872, DOI: 10.1111/j.1600-065X.1982.tb00392.x
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 57, 1984, pages 6851 - 6855
MORRISON ET AL., ADV. IMMUNOL., vol. 44, 1988, pages 65 - 92
VERHOEYEN ET AL., SCIENCE, vol. 240, 1988, pages 1038 - 1040
PADLAN, MOLEC. IMMUN., vol. 25, 1991, pages 489 - 498
PADLAN, MOLEC. IMMUN., vol. 31, 1994, pages 169 - 217
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 55, 1988, pages 5879 - 5883
WARD ET AL., NATURE, vol. 334, 1989, pages 544 - 554
HUSTON ET AL., METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88
SHU ET AL., PROC. NATL. SCI. USA, vol. 90, 1993, pages 1995 - 1999
LEVY ET AL., SCIENCE, vol. 228, 1985, pages 1202
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
GILLIES ET AL., J. IMMUNOL. METHODS, vol. 125, 1989, pages 191 - 202
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323
PADLAN, MOLECULAR IMMUNOLOGY, vol. 28, no. 4/5, 1991, pages 489 - 498
STUDNICKA ET AL., PROTEIN ENGINEERING, vol. 7, no. 6, 1994, pages 805 - 814
ROGUSKA ET AL., PROC. NATL. SCI. USA, vol. 91, 1994, pages 969 - 973
HUSZAR, INT. REV. IMMUNOL., vol. 73, 1995, pages 65 - 93
JESPERS ET AL., BIO/TECHNOLOGY, vol. 72, 1988, pages 899 - 903
CHOTHIA ET AL., J. MOL. BIOL., vol. 278, 1998, pages 457 - 479
NEUBERGER ET AL., NATURE, vol. 372, 1984, pages 604 - 608
TAKEDA ET AL., NATURE, vol. 314, 1985, pages 452 - 454
NEWMAN, BIOTECHNOLOGY, vol. 10, 1992, pages 1455 - 1460
JOLIOT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 1864 - 1868
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574 - 365
SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 201
BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507
"Medical Applications of Controlled Release", 1974, CRC PRES.
GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351
HOWARD ET AL., J. NEUROSURG., vol. 71, 1989, pages 105
WUWU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
See also references of EP 3383916A4
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: